Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 5/20 | 0.48 |
| ▸ | BCHE | P06276 | 5/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989170 | 0.94 | USP2 (0.47) | USP2CYP3A4THRBACHEBCHE | |
| SCHEMBL467676 | 0.76 | DRD4 (0.49) | USP2CYP3A4THRBACHEBCHE | |
| SCHEMBL15127507 | 0.76 | DRD4 (0.49) | USP2CYP3A4THRBACHEBCHE | |
| SCHEMBL14923037 | 0.76 | USP2 (0.45) | USP2CYP3A4THRBACHEBCHE | |
| SCHEMBL10390269 | 0.74 | USP2 (0.59) | USP2CYP3A4THRBACHEBCHE | |
| SCHEMBL10263413 | 0.72 | USP2 (0.45) | USP2CYP3A4THRBACHEBCHE | |
| SCHEMBL10202352 | 0.72 | DRD4 (0.45) | USP2CYP3A4THRBACHEBCHE | |
| SCHEMBL2739528 | 0.71 | ALDH1A1 (0.49) | ACHEBCHENPC1MAPTKDM4E | |
| SCHEMBL12160443 | 0.71 | MAPT (0.53) | USP2CYP3A4THRBACHEBCHE | |
| SCHEMBL23143476 | 0.68 | DRD4 (0.47) | BCHEDRD4CYP2A6MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3889148-A1 | AXL TYROSINE RECEPTOR KINASE INHIBITOR \"R428\" IN PURIFIED FORM | BerGenBio ASA (NO) | 2021-10-06 | — | — | EP | claimed |
| EP-3218367-B1 | PROCESS FOR THE PURIFICATION OF THE AXL TYROSINE RECEPTOR KINASE INHIBITOR \"R428\ | BERGENBIO ASA (NO) | 2021-05-19 | — | — | EP | claimed |
| US-9994553-B2 | Process for the purification of the Axl tyrosine receptor kinase inhibitor “R428” | BERGENBIO AS (NO) | 2018-06-12 | — | — | US | claimed |
| US-20170334884-A1 | PROCESS FOR THE PURIFICATION OF THE AXL TYROSINE RECEPTOR KINASE INHIBITOR \"R428\ | BERGENBIO ASA (NO) | 2017-11-23 | — | — | US | claimed |
| EP-3218367-A1 | PROCESS FOR THE PURIFICATION OF THE AXL TYROSINE RECEPTOR KINASE INHIBITOR \"R428\ | BerGenBio AS (NO) | 2017-09-20 | — | — | EP | claimed |
| WO-2016075477-A9 | PROCESS FOR THE PURIFICATION OF THE AXL TYROSINE RECEPTOR KINASE INHIBITOR \"R428\ | BERGENBIO AS (NO) | 2017-07-06 | — | — | WO | claimed |
| WO-2016075477-A1 | PROCESS FOR THE PURIFICATION OF THE AXL TYROSINE RECEPTOR KINASE INHIBITOR \"R428\ | BERGENBIO AS (NO) | 2016-05-19 | — | — | WO | claimed |
| WO-2022268026-A1 | 1,2,4-TRIAZOLE COMPOUNDS AS AXL INHIBITORS | 南京正大天晴制药有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20210379064-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | MIDCAP FINANCIAL TRUST | 2021-12-09 | — | — | US | disclosed |
| US-20210379064-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | MIDCAP FINANCIAL TRUST | 2021-12-09 | — | — | US | disclosed |
| EP-3889148-A1 | AXL TYROSINE RECEPTOR KINASE INHIBITOR \"R428\" IN PURIFIED FORM | BerGenBio ASA (NO) | 2021-10-06 | — | — | EP | disclosed |
| EP-3218367-B1 | PROCESS FOR THE PURIFICATION OF THE AXL TYROSINE RECEPTOR KINASE INHIBITOR \"R428\ | BERGENBIO ASA (NO) | 2021-05-19 | — | — | EP | disclosed |
| US-20190336500-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. | 2019-11-07 | — | — | US | disclosed |
| US-20080188454-A1 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188454-A1 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188454-A1 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2008083367-A2 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008083353-A1 | BICYCLIC ARYL AND BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336500-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | USP2 1865/4885CYP3A4 4671/4885THRB 322/4885 |
| US-20170334884-A1 | PROCESS FOR THE PURIFICATION OF THE AXL TYROSINE RECEPTOR KINASE INHIBITOR \"R428\ | AXL, TYRO3, RET | USP2 3155/4885CYP3A4 3779/4885THRB 59/4885 |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | USP2 2125/4885CYP3A4 3592/4885THRB 80/4885 |
| US-20210379064-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | USP2 1865/4885CYP3A4 4671/4885THRB 322/4885 |
| US-20080188454-A1 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | AXL, FLT3, FLT1 | USP2 1638/4885CYP3A4 3175/4885THRB 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.